Based on the finding that HIF-1α interacts with p53 and inhibits its transcriptional activity in hypoxic cancer cells, Topotecan (TPT), a topoisomerase inhibitor used in ovarian cancer treatment, was reported to downregulate HIF-1α in hypoxic cells to enhance p53 transcriptional activities and restore p53 tumor-suppressive function, which may offer a novel approach to reverse hypoxia-related cisplatin and paclitaxel resistance in ovarian cancers expressing WT p53 (Parmakhtiar et al., 2019). This evidence concerns the gene TP53 and ovarian carcinoma.